Forte Biosciences Inc
FBRX
NASDAQ
Biotechnology
$76.83
USD
-0.03 (-0.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.57B
Volume 490.1K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-87.94M
TTM
-107.1%
YoY
Operating Cash Flow
$-71.98M
TTM
-86.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.0 | 3.2 | 2.8 | 2.0 | 2.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.6 | 18.4 | 24.6 | 22.4 | 24.6 |
Operating Income | -11.6 | -18.4 | -24.6 | -22.4 | -24.6 |
EBITDA | -11.6 | -18.4 | -24.6 | -22.4 | -24.6 |
Other Income / Expense | 0.3 | 0.7 | -1.9 | 0.7 | 1.5 |
Total Other Income / Expense | 0.3 | 0.7 | 0.8 | 0.7 | 1.5 |
Income Before Income Taxes | -11.2 | -17.7 | -23.8 | -21.8 | -23.1 |
Income Taxes | 0.0 | 0.0 | 1.0 | 0.4 | 0.2 |
Net Income | -11.2 | -17.7 | -24.8 | -22.1 | -23.3 |
Consolidated Net Income / Loss | -11.2 | -17.7 | -24.8 | -22.1 | -23.3 |
Net Income Attributable to Common Shareholders | -11.2 | -17.7 | -24.8 | -22.1 | -23.3 |
Basic EPS | -$0.96 | -$0.99 | -$1.38 | -$1.24 | -$0.97 |
Diluted EPS | -$0.96 | -$0.99 | -$1.38 | -$1.24 | -$0.97 |
Basic Shares Outstanding | 11.7M | 17.8M | 17.9M | 17.8M | 23.8M |
Diluted Shares Outstanding | 11.7M | 17.8M | 17.9M | 17.8M | 23.8M |